Chemotherapy Plus P53 Gene Therapy May Help Treat
Post# of 72447
(Total Views: 1233)
Posted On: 05/25/2017 11:43:00 PM
Chemotherapy Plus P53 Gene Therapy May Help Treat Locally Advanced Cervical Cancer
"Results showed that both treatments induced different efficacy responses. Indeed, 95% of patients in the combined group saw benefits: two complete responses, 17 partial responses, and one stable disease, compared to 75% of patients in the PVB group: 15 partial responses and five patients with stable disease. The tumor size was significantly decreased by more than 15 cm2 in the combined group, compared to approximately 11.5 cm2 in the PVB group."
https://cervicalcancernews.com/2017/05/24/neo...al-cancer/
Since Kevetrin has the ability to chemosensitize, its combination therapy possibilities are endless.
"The Company’s previously reported mechanism of action (MOA) of Kevetrin strongly suggests that Kevetrin has great potential to enhance chemosensitivity. Multiple reports from different laboratories have shown that drugs modulating any of these: p531, HDAC2, c-MYC3(p53:Clin. Can. Research 2009 15, 6495-502; HDAC: Cancer Sci 2008 99, 378-84; c-Myc: Biomed Pharmacother 2015 73, 123-128) has shown enhanced sensitivity to chemotherapeutic drugs. p53 is major determinant of chemosensitivity in humans while mutant p53 proteins can induce drug resistance. Since Kevetrin modulates all of the above molecules, laboratory studies tested the sensitizing ability in mutant p53 cells and tumors which are refractory to chemotherapeutic agents. The combination of Kevetrin with chemotherapy drugs resulted in synergistic apoptosis at a much lower concentrations than with each agent individually. Thus, Kevetrin holds promise to maximize tumor cell killing when used in combination therapies. Laboratory studies conducted by Cellceutix and at leading institutions on the effects of Kevetrin in combination with approved cancer drugs, including studies against renal cancer, pancreatic cancer, ovarian cancer, glioblastoma and acute myeloid leukemia, have delivered promising data supporting the ability of Kevetrin to enhance chemosensitivity."
http://www.cellceutix.com/press-release-2/201...ensitivity
"Results showed that both treatments induced different efficacy responses. Indeed, 95% of patients in the combined group saw benefits: two complete responses, 17 partial responses, and one stable disease, compared to 75% of patients in the PVB group: 15 partial responses and five patients with stable disease. The tumor size was significantly decreased by more than 15 cm2 in the combined group, compared to approximately 11.5 cm2 in the PVB group."
https://cervicalcancernews.com/2017/05/24/neo...al-cancer/
Since Kevetrin has the ability to chemosensitize, its combination therapy possibilities are endless.
"The Company’s previously reported mechanism of action (MOA) of Kevetrin strongly suggests that Kevetrin has great potential to enhance chemosensitivity. Multiple reports from different laboratories have shown that drugs modulating any of these: p531, HDAC2, c-MYC3(p53:Clin. Can. Research 2009 15, 6495-502; HDAC: Cancer Sci 2008 99, 378-84; c-Myc: Biomed Pharmacother 2015 73, 123-128) has shown enhanced sensitivity to chemotherapeutic drugs. p53 is major determinant of chemosensitivity in humans while mutant p53 proteins can induce drug resistance. Since Kevetrin modulates all of the above molecules, laboratory studies tested the sensitizing ability in mutant p53 cells and tumors which are refractory to chemotherapeutic agents. The combination of Kevetrin with chemotherapy drugs resulted in synergistic apoptosis at a much lower concentrations than with each agent individually. Thus, Kevetrin holds promise to maximize tumor cell killing when used in combination therapies. Laboratory studies conducted by Cellceutix and at leading institutions on the effects of Kevetrin in combination with approved cancer drugs, including studies against renal cancer, pancreatic cancer, ovarian cancer, glioblastoma and acute myeloid leukemia, have delivered promising data supporting the ability of Kevetrin to enhance chemosensitivity."
http://www.cellceutix.com/press-release-2/201...ensitivity
(3)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
